Sanctuary Advisors LLC Sells 24,735 Shares of Organon & Co. (NYSE:OGN)

Sanctuary Advisors LLC lowered its holdings in Organon & Co. (NYSE:OGN) by 9.2% in the third quarter, HoldingsChannel.com reports. The firm owned 243,855 shares of the company’s stock after selling 24,735 shares during the quarter. Sanctuary Advisors LLC’s holdings in Organon & Co. were worth $4,665,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of OGN. SG Americas Securities LLC acquired a new position in Organon & Co. in the 2nd quarter valued at $180,000. Wealth Enhancement Advisory Services LLC increased its position in shares of Organon & Co. by 17.4% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 45,406 shares of the company’s stock worth $940,000 after purchasing an additional 6,737 shares during the period. Nisa Investment Advisors LLC grew its stake in Organon & Co. by 84.1% during the second quarter. Nisa Investment Advisors LLC now owns 74,865 shares of the company’s stock worth $1,550,000 after buying an additional 34,200 shares in the last quarter. Pallas Capital Advisors LLC acquired a new position in shares of Organon & Co. in the 2nd quarter valued at approximately $326,000. Finally, Eads & Heald Wealth Management bought a new position in Organon & Co. in the second quarter valued at approximately $216,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Trading Down 0.3 %

OGN opened at $15.30 on Monday. The stock has a market cap of $3.94 billion, a PE ratio of 3.04, a price-to-earnings-growth ratio of 0.73 and a beta of 0.75. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a twelve month low of $12.62 and a twelve month high of $23.10. The company has a fifty day moving average of $16.46 and a 200-day moving average of $19.17.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). The business had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. Organon & Co.’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period last year, the firm posted $0.78 earnings per share. On average, sell-side analysts predict that Organon & Co. will post 3.89 EPS for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 7.32%. The ex-dividend date of this dividend was Tuesday, November 12th. Organon & Co.’s payout ratio is 22.22%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. cut Organon & Co. from a “neutral” rating to an “underweight” rating and increased their price target for the company from $18.00 to $20.00 in a research note on Friday, September 6th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.